» Articles » PMID: 38162775

Exploring the Potential Association Between COVID-19 and Thyroid Cancer: A Mendelian Randomization Study

Overview
Journal ACS Omega
Specialty Chemistry
Date 2024 Jan 1
PMID 38162775
Authors
Affiliations
Soon will be listed here.
Abstract

In order to address the ongoing debate surrounding the potential link between COVID-19 and thyroid cancer, our study was specifically designed to investigate the association between these two factors. We acquired summary data from a genome-wide association study (GWAS) concerning COVID-19 susceptibility and severity of COVID-19 in the European population, with a focus on their relationship with thyroid cancer. We applied three distinct methodologies to evaluate the causality between COVID-19 and thyroid cancer, employing Mendelian randomization (MR)-Egger, weighted median (WM), and inverse variance-weighted (IVW) approaches. Furthermore, we utilized a variety of techniques to assess pleiotropy and heterogeneity, including the MR-Egger intercept, MR-pleiotropy residual sum and outlier method (PRESSO), and Cochran's test. The MR analysis revealed associations between the susceptibility of COVID-19 and thyroid cancer (IVW odds ratio [OR]: 2.826, 95% confidence interval [CI]: [0.842, 9.483], = 0.093) as well as between the risk of COVID-19 hospitalization and thyroid cancer (IVW OR: 1.630, 95% CI: [1.050, 2.529], = 0.029). However, the relationship between COVID-19 and the occurrence of severe thyroid cancer cases was less evident (IVW OR: 1.061, 95% CI: [0.575, 1.956], = 0.850). Our sensitivity analyses did not reveal any signs of horizontal pleiotropy or heterogeneity. Our MR study provided compelling evidence supporting a causal connection between the risk of COVID-19 hospitalization and thyroid cancer. Nevertheless, the MR results derived from genetic data do not support a causal link between susceptibility to COVID-19 and the risk of thyroid cancer or between very severe cases of COVID-19 and the risk of thyroid cancer. These findings have significant implications for further investigations into the impact of COVID-19 on health and the etiology of thyroid cancer.

Citing Articles

Application of Mendelian randomization in thyroid diseases: a review.

Li Z, Wang R, Liu L, Jia Z, Zhou P, He Q Front Endocrinol (Lausanne). 2025; 15:1472009.

PMID: 39749022 PMC: 11693456. DOI: 10.3389/fendo.2024.1472009.


Thyroid Density in CT Imaging as a Potential Marker of Lung Involvement in COVID-19: A Retrospective Analysis.

Balasubramaniam S, Suresh Kumar A, Pandian P, Raviganesh P, Perumpallipatty Kumarasamy S, Raju B Cureus. 2024; 16(5):e59699.

PMID: 38841002 PMC: 11150337. DOI: 10.7759/cureus.59699.

References
1.
Manson J, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T . COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020; 2(10):e594-e602. PMC: 7442426. DOI: 10.1016/S2665-9913(20)30275-7. View

2.
Hemani G, Zheng J, Elsworth B, Wade K, Haberland V, Baird D . The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018; 7. PMC: 5976434. DOI: 10.7554/eLife.34408. View

3.
Skrivankova V, Richmond R, Woolf B, Yarmolinsky J, Davies N, Swanson S . Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021; 326(16):1614-1621. DOI: 10.1001/jama.2021.18236. View

4.
Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A . Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020; 10(7):935-941. PMC: 7334098. DOI: 10.1158/2159-8290.CD-20-0516. View

5.
Burgess S, Thompson S . Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011; 40(3):755-64. DOI: 10.1093/ije/dyr036. View